French biotechnology company Orakl Oncology has raised $34 million to accelerate the development of its artificial intelligence-powered cancer drug discovery platform, which combines patient-derived tumour models with advanced data analysis to identify and evaluate potential cancer treatments.
The investment represents a significant milestone for the Paris-based company, which is developing an approach intended to improve the predictability of preclinical cancer research and reduce the risk of failure during drug development.
Orakl Oncology was co-founded by Dr Fanny Jaulin, a cancer researcher and entrepreneur whose work focuses on understanding tumour biology and developing more effective methods for evaluating potential therapies.
The company’s technology combines biological experiments using patient-derived cancer models with computational analysis. By studying how tumour samples respond to different treatments, Orakl aims to generate data that can help researchers identify promising drug candidates and understand why certain therapies may work for particular groups of patients.
Traditional oncology drug development faces significant challenges because experimental models do not always accurately reproduce the complexity of human cancers. This can result in treatments that appear promising during laboratory testing but fail to demonstrate sufficient effectiveness in clinical trials.
Orakl’s approach is designed to address this problem by using patient-derived tumour models that retain important characteristics of the original cancer. The company integrates experimental findings with machine learning to generate insights into treatment response and support more informed drug development decisions.
The new capital will support further development of the company’s technology, expansion of its research capabilities and advancement of its oncology programmes.
The funding also reflects increasing investor interest in biotechnology companies combining artificial intelligence with experimental biological data to improve the efficiency and precision of pharmaceutical research.
Under Jaulin’s leadership, Orakl Oncology is positioning itself at the intersection of cancer biology, artificial intelligence and precision medicine, with the aim of developing technologies that can better predict how patients may respond to potential treatments.
Although the platform is designed to improve early-stage research, its ability to translate these insights into successful clinical treatments will depend on further development and validation.
The investment marks another step in Orakl Oncology’s efforts to build a more predictive approach to cancer drug discovery, while highlighting the growing role of women entrepreneurs and scientists in the biotechnology industry.
